Compare Summit Therapeutics Inc (SMMT) vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Summit Therapeutics Inc trades at $14.65 (market cap $10.48B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $46.99. The key difference: Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | USOI | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $29.32 | $61.17 |
52-Week Low | $13.05 | $42.27 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
USOI, the Credit Suisse X-Links Crude Oil Shares Covered Call ETN, trades at $46.84, up 0.09% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The instrument's exceptionally high yield, cited as over 30% by 24/7 Wall Street on 2026-05-19, draws investor attention amid oil market volatility driven by geopolitical events like the Iran War, as reported on 2026-04-26. Key support sits at $45 with resistance at $47.
The outlook hinges on crude oil price movements and covered call strategy performance, offering high income potential but carrying significant risks from oil volatility and the ETN structure, which differs from traditional ETFs. Investors face concentration risk in energy markets and potential capital erosion if oil trends lower.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →
